Valuation : Evaxion A/S

Market Cap 26.02M 22.39M 21.07M 19.24M 36M 2.46B 36.1M 249M 96.6M 1.26B 97.71M 95.58M 4.06B P/E 2026 *
-78x
P/E 2027 * -208x
Enterprise Value 26.02M 22.39M 21.07M 19.24M 36M 2.46B 36.1M 249M 96.6M 1.26B 97.71M 95.58M 4.06B EV / Sales 2026 *
-
EV / Sales 2027 * 5.57x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.30%
1 week+3.65%
Current month+4.00%
1 month+4.70%
3 months-12.11%
6 months-8.24%
Current year-34.59%
1 week 2.9
Extreme 2.9
3.19
1 month 2.83
Extreme 2.83
3.64
Current year 2.77
Extreme 2.77
5.48
1 year 2.71
Extreme 2.7094
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 24/11/2025
Corporate Officer/Principal 49 11/08/2008
Director of Finance/CFO 53 01/11/2024
Director TitleAgeSince
Chairman 58 25/11/2020
Director/Board Member 56 01/01/2018
Director/Board Member 68 25/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
4/16/26 A Other

Director

2,376 0.0006%
3/18/26 A Other

Chief Financial Officer

645,750 0.1549%
3/18/26 A OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%+3.65%+6.85%-92.20% 26.02M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.70%+0.85%+66.58%+87.21% 27.5B
Weighted average by Cap. -1.03%+0.11%+89.41%+127.91%

Financials

2026 *2027 *
Net sales - 4.67M 4.02M 3.78M 3.45M 6.46M 441M 6.48M 44.68M 17.34M 226M 17.54M 17.15M 729M
Net income -15.56M -13.39M -12.6M -11.51M -21.53M -1.47B -21.59M -149M -57.77M -754M -58.43M -57.16M -2.43B -11.81M -10.17M -9.56M -8.74M -16.34M -1.12B -16.39M -113M -43.85M -572M -44.36M -43.39M -1.84B
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
04/09/26 $3.120 +1.30% 38,328
03/09/26 $3.080 +0.33% 39,611
02/09/26 $3.070 +3.02% 60,661
01/09/26 $2.980 -0.67% 63,034
31/08/26 $3.000 -0.33% 102,016
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.120USD
Average target price
11.25USD
Spread / Average Target
+260.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock